Volixibat

Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

Retrieved on: 
Monday, November 13, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Sleep, Hepatology, MDR3, Self-harm, Safety, Hepatocellular carcinoma, Bilirubin, Cholestasis, AASLD, Liver, Disease, Risk, Cholestatic pruritus, Hematology, Quality of life (healthcare), MYO5B, PFIC, Patient, Publication, Pregnancy, Nature, TJP2, Ascending cholangitis, GI, Hippeastrum mirum, Liver support system, Volixibat, ICP, IBAT, Progressive familial intrahepatic cholestasis, FIC, Augmented fifth, Growth, Doctor of Philosophy, Quality of life, AND, Itch, Medication, MCID, HIV disease progression rates, SBA, Chloride, Pharmaceutical industry, Nursing, Medical imaging, Dietary supplement, Boston, BSEP

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced new data from its LIVMARLI and volixibat programs presented at The Liver Meeting®, the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, Massachusetts.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced new data from its LIVMARLI and volixibat programs presented at The Liver Meeting®, the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, Massachusetts.
  • “PFIC is a chronic, debilitating cholestatic liver disease characterized by elevated bile acids and pruritus so severe that patients can be listed for liver transplant even in the absence of disease progression.
  • These data suggest overall improved liver health with maralixibat treatment in patients with PFIC that can be maintained long-term.
  • No clinically meaningful changes in liver enzyme levels or hematology parameters were observed after volixibat treatment.

Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 3, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Exercise, ALGS, Partnership, CTX, Spiroplasma mirum, Event, Hepatology, Travers Smith, PBC, VISTAS, Prescription Drug User Fee Act, Primary sclerosing cholangitis, Biliary atresia, CAMEO, Sale, Medication, Alagille syndrome, Cholic acid, Primary biliary cholangitis, Shanda, Acquisition, Patient, Investment, Itch, Bilirubin, PDUFA, Webcast, Therapy, PSC, Cholestatic pruritus, Volixibat, Pharmaceutical industry, Security (finance), Video game

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for second quarter 2023 and provided a business update.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for second quarter 2023 and provided a business update.
  • Mirum to pay $210 million upfront and up to $235 million in potential tiered annual net sales-based milestones.
  • Second quarter 2023 global net sales grew 86% as compared to second quarter 2022, on track for 50% US net product sales growth in 2023 as compared to 2022.
  • Total operating expenses were $61.8 million for the quarter ended June 30, 2023 in comparison to $48.9 million for the quarter ended June 30, 2022.

Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 4, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Exercise, Spiroplasma mirum, European Medicines Agency, Food and Drug Administration, Prescription Drug User Fee Act, Primary sclerosing cholangitis, Biliary atresia, Medication, Primary biliary cholangitis, Shanda, Patient, Investment, PDUFA, Liver, Alagille syndrome, PFIC, Food, Volixibat, Pharmaceutical industry, Video game, Security (finance)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and provided a business update.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2023 and provided a business update.
  • Total net product sales of LIVMARLI for the quarter ended March 31, 2023 was $29.1 million compared to $10.9 million for the quarter ended March 31, 2022.
  • Total operating expenses were $58.7 million for the quarter ended March 31, 2023 in comparison to $45.6 million for the quarter ended March 31, 2022.
  • As of March 31, 2023, Mirum had cash, cash equivalents, restricted cash equivalents, and short-term investments of $232.1 million.

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 8, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, New Drug Application, Webcast, Biliary atresia, PFIC, The Journal of Pediatrics, Growth, Spiroplasma mirum, Volixibat, Event, Itch, Sale, AASLD, IBAT, Quality of life, Patient, Shanda, European Commission, Food, Investment, Pediatrics, Primary sclerosing cholangitis, Food and Drug Administration, Alagille syndrome, Primary biliary cholangitis, Sleep, Medication, Pharmaceutical industry, Satellite navigation device, Cryptocurrency

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2022 and provided a business update.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2022 and provided a business update.
  • Published LIVMARLI data highlighting quality of life and sleep improvements in patients with Alagille syndrome in the Journal of Pediatrics.
  • As of December 31, 2022, Mirum had cash, cash equivalents, restricted cash equivalents, and short-term investments of $251.7 million.
  • Mirum will host a conference call today, March 8, 2022, at 1:30 p.m. PT/4:30 p.m.

Mirum Pharmaceuticals Provides Development Program Updates

Retrieved on: 
Tuesday, November 29, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Growth, Itch, IBAT, Cholestasis, ICP, Recycling, LDL, European Directive on Traditional Herbal Medicinal Products, PSC, Alagille syndrome, Patient, Medication, Royal commission, Primary biliary cholangitis, European Commission, CHMP, Security (finance), Primary sclerosing cholangitis, VISTAS, PBC, PFIC, Biliary atresia, Spiroplasma mirum, Cholestatic pruritus, European Committee of the Regions, Pregnancy, Institute of Liver and Biliary Sciences, Liver, Volixibat, Pharmaceutical industry, Food delivery

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the decision to discontinue the OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to enrollment feasibility.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the decision to discontinue the OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to enrollment feasibility.
  • Mirum is continuing to advance its broad pipeline of indications where LIVMARLI and volixibat have the potential for life-changing impact for patients.
  • Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases.
  • In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 4, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, FDA, Stomach, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vomiting, Liver, Nausea, Securities and Exchange Commission (Philippines), Institute of Liver and Biliary Sciences, Abdomen, Vitamin, Primary biliary cholangitis, VISTAS, Gastrointestinal bleeding, European Medicines Agency, Private Securities Litigation Reform Act, Pregnancy, IBAT, Breakthrough therapy, Cholestatic pruritus, Security (finance), Pain, Alagille syndrome, Diarrhea, Bone, FSV, Pain scale, Recycling, Patient, Marketing, Event, COVID-19, Spiroplasma mirum, Adult, Liver injury, Skin, PFIC, Cholestasis, Biliary atresia, Primary sclerosing cholangitis, Webcast, Vitamin A, LDL, Food, Volixibat, Symptoms of COVID-19, Pharmaceutical industry, Medical imaging

LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS, PFIC and biliary atresia.

Key Points: 
  • LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS, PFIC and biliary atresia.
  • To learn more about ongoing clinical trials with LIVMARLI, please visit Mirums clinical trials section on the companys website.
  • Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases.
  • Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals

Retrieved on: 
Monday, May 23, 2022
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Food, IBAT, U.S. Securities and Exchange Commission, LDL, Gastrointestinal bleeding, Liver, Stomach, Abdomen, Vitamin, Biliary atresia, Breakthrough therapy, Cholestatic pruritus, Private Securities Litigation Reform Act, PFIC, Pain scale, Bone, Pain, Nausea, Symptoms of COVID-19, Vitamin A, COVID-19, VISTAS, Vomiting, Liver injury, Acquisition, Diarrhea, Achievement, FSV, Pregnancy, Adult, FDA, Cholestasis, European Medicines Agency, Human, Skin, Security (finance), Recycling, Institute of Liver and Biliary Sciences, Volixibat, Economics, Primary sclerosing cholangitis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, Patient, Book, Marketing, Liver disease, Medication, Primary biliary cholangitis, Alagille syndrome, Pharmaceutical industry, Medical imaging, Spiroplasma mirum

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has acquired Satiogen Pharmaceuticals, Inc., a San Diego-based company.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has acquired Satiogen Pharmaceuticals, Inc., a San Diego-based company.
  • Satiogen, now a wholly-owned Mirum subsidiary, was an existing licensing partner for LIVMARLI (maralixibat) oral solution and volixibat.
  • Through the transaction, Mirum obtained all Satiogen licensing payments and Satiogen-owned intellectual property relating to LIVMARLI and volixibat.
  • Mirum will wholly own the Satiogen subsidiary, which will receive a 2% royalty.

Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 5, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Cholestatic pruritus, Interim, Cholestasis, LDL, Pain scale, Biliary atresia, Vitamin, Skin, Medication, PFIC, Event, Nausea, Stomach, Pain, Liver injury, Patient, INDIGO, FDA, SG, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gastrointestinal bleeding, Breakthrough therapy, Liver, VISTAS, Itch, Vomiting, U.S. Securities and Exchange Commission, Investment, Private Securities Litigation Reform Act, Vitamin A, Primary sclerosing cholangitis, Pregnancy, Research, Diarrhea, Symptoms of COVID-19, Security (finance), Volixibat, Marketing, Growth, Bone, COVID-19, Nasdaq, European Medicines Agency, Food, Abdomen, Institute of Liver and Biliary Sciences, FSV, Webcast, Alagille syndrome, Adult, Primary biliary cholangitis, Recycling, IBAT, Pharmaceutical industry, Medical imaging, Video game, Reinsurance, Spiroplasma mirum

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
  • Interim analysis expected for VISTAS Phase 2b clinical trial for primary sclerosing cholangitis in the fourth quarter of 2022.
  • Interim analysis expected for OHANA Phase 2b clinical trial for intrahepatic cholestasis of pregnancy in the fourth quarter of 2022.
  • License revenue for the quarter ended March 31, 2022 was $2.0 million, compared to none for the first quarter of 2021.

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 9, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Cholestasis, Nasdaq, Medication, Spiroplasma mirum, PRV, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prescription, Patient, Growth, Cholestatic pruritus, Food, Medicine, Pharmaceutical industry, Alagille syndrome, LIVMARLI® (maralixibat) oral solution, Volixibat, Mirum Pharmaceuticals, LIVMARLI® (MARALIXIBAT) ORAL SOLUTION, VOLIXIBAT, MIRUM PHARMACEUTICALS

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2021 and provided a business update.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2021 and provided a business update.
  • Total net product revenue from the sale of LIVMARLI for the fourth quarter and year ended December 31, 2021 was $3.1 million, compared to none for the fourth quarter and year ended 2020.
  • Total operating expenses for the fourth quarter ended December 31, 2021 were $48.7 million, compared to $37.0 million for the fourth quarter of 2020.
  • Research and development expenses for the fourth quarter ended December 31, 2021 were $27.8 million, compared to $29.7 million for the comparable prior-year period.

Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 15, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Nausea, Stomach, Form, Pregnancy, Symptoms of COVID-19, Form 10-K, Cholestasis, Liver, Abdomen, Vitamin, Alagille syndrome, LDL, Breakthrough therapy, IBAT, Gastrointestinal bleeding, Food, European Medicines Agency, Vitamin A, Diarrhea, Spiroplasma mirum, Recycling, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biliary atresia, Institute of Liver and Biliary Sciences, VISTAS, Primary sclerosing cholangitis, Vomiting, Pain, Marketing, Event, Primary biliary cholangitis, Volixibat, Cholestatic pruritus, PFIC, SEC, Liver injury, Pain scale, FSV, Webcast, Form 10-Q, Patient, Skin, FDA, Bone, Adult, Pharmaceutical industry, Medical imaging, LIVMARLI™ (maralixibat) oral solution, Volixibat, Mirum Pharmaceuticals, Inc., LIVMARLI™ (MARALIXIBAT) ORAL SOLUTION, VOLIXIBAT, MIRUM PHARMACEUTICALS, INC.

LIVMARLI is currently being evaluated in late-stage clinical studies in other rare cholestatic liver diseases including progressive familial intrahepatic cholestasis and biliary atresia.

Key Points: 
  • LIVMARLI is currently being evaluated in late-stage clinical studies in other rare cholestatic liver diseases including progressive familial intrahepatic cholestasis and biliary atresia.
  • LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS, PFIC and biliary atresia.
  • To learn more about ongoing clinical trials with LIVMARLI, please visit Mirums clinical trials section on the companys website.
  • Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases.